Results 121 to 130 of about 21,874 (160)
Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer. [PDF]
Br J CancerSteggall J +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2007
▲ Lapatinib inhibits tyrosine phosphorylation of both epidermal growth factor receptor and human epidermal receptor (HER) 2, thus preventing receptor activation. ▲ Preliminary evidence suggests that clinical response to lapatinib may be linked to the extent of baseline HER2 gene expression.
Sohita, Dhillon, Antona J, Wagstaff
+7 more sources
▲ Lapatinib inhibits tyrosine phosphorylation of both epidermal growth factor receptor and human epidermal receptor (HER) 2, thus preventing receptor activation. ▲ Preliminary evidence suggests that clinical response to lapatinib may be linked to the extent of baseline HER2 gene expression.
Sohita, Dhillon, Antona J, Wagstaff
+7 more sources
Reactions Weekly, 2018
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases plays an important role in the biology of many cancers. In breast and gastrointestinal cancer, and at lower rates also in additional tumor types, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival. Breast cancer
Minna, Voigtlaender +2 more
+5 more sources
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases plays an important role in the biology of many cancers. In breast and gastrointestinal cancer, and at lower rates also in additional tumor types, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival. Breast cancer
Minna, Voigtlaender +2 more
+5 more sources
Reactions Weekly, 2010
Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens. We present results on preapproval drug access for this combination in such patients occurring in the ...
Kroep, J. R. +11 more
+5 more sources
Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens. We present results on preapproval drug access for this combination in such patients occurring in the ...
Kroep, J. R. +11 more
+5 more sources
2014
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases plays an important role in the biology of many cancers. In breast and gastric cancer, and maybe also additional tumor types, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival.
Nolting, Minna +2 more
openaire +3 more sources
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases plays an important role in the biology of many cancers. In breast and gastric cancer, and maybe also additional tumor types, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival.
Nolting, Minna +2 more
openaire +3 more sources
Lapatinib: A comprehensive profile
2023Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the
Ahmed A, Abdelgalil, Hamad M, Alkahtani
openaire +2 more sources
Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin
American Journal of Clinical Oncology, 2008To evaluate the safety/tolerability and potential antitumor activity of lapatinib, at dose ranges of 1000 to 1500 mg/d, in combination with gemcitabine and gemcitabine/oxaliplatin (GEMOX) in patients with advanced pancreaticobiliary cancer.Patients with advanced pancreaticobiliary cancer were assigned to 1 of 4 cohorts of lapatinib administered once ...
Howard, Safran +11 more
openaire +2 more sources